Jade Biosciences’ (JBIO) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Jade Biosciences (NASDAQ:JBIO) in a report released on Thursday morning, MarketBeat Ratings reports. The firm currently has a $55.00 price objective on the stock.

Other equities analysts have also issued reports about the company. Wall Street Zen lowered Jade Biosciences from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 12th. BTIG Research increased their target price on shares of Jade Biosciences from $74.00 to $77.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Jade Biosciences in a report on Friday, September 11th. Jefferies Financial Group reaffirmed a “buy” rating and set a $48.00 price target on shares of Jade Biosciences in a research report on Tuesday, August 11th. Finally, Wedbush reiterated an “outperform” rating and set a $47.00 price objective on shares of Jade Biosciences in a research note on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $51.75.

Jade Biosciences Trading Up 2.5%

Shares of JBIO opened at $14.12 on Thursday. Jade Biosciences has a twelve month low of $8.20 and a twelve month high of $28.00. The firm has a market capitalization of $898.03 million, a P/E ratio of -7.35 and a beta of 1.64. The stock’s fifty day simple moving average is $19.46 and its 200 day simple moving average is $19.70.

Jade Biosciences (NASDAQ:JBIO) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). Sell-side analysts predict that Jade Biosciences will post -2.89 earnings per share for the current year.

Institutional Investors Weigh In On Jade Biosciences

A number of large investors have recently modified their holdings of the stock. Engineers Gate Manager LP acquired a new position in Jade Biosciences during the 2nd quarter worth approximately $503,000. Maven Securities LTD purchased a new position in Jade Biosciences in the 2nd quarter worth approximately $1,111,000. Squarepoint Ops LLC grew its position in Jade Biosciences by 22.0% in the second quarter. Squarepoint Ops LLC now owns 54,456 shares of the company’s stock valued at $1,210,000 after acquiring an additional 9,806 shares in the last quarter. Corient Private Wealth LP acquired a new stake in Jade Biosciences in the second quarter valued at approximately $1,367,000. Finally, Bank of New York Mellon Corp acquired a new stake in Jade Biosciences in the second quarter valued at approximately $1,896,000.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. The company’s research and development efforts are directed toward antibody-based medicines designed to address significant unmet needs in immune-mediated conditions.

Jade’s pipeline includes investigational therapeutic programs intended to modulate biological pathways involved in inflammation and immune-system activity. As a development-stage company, its products remain subject to clinical testing and regulatory review, and there is no assurance that any candidate will receive approval or reach the commercial market.

The company is headquartered in the United States and is developing its portfolio for potential use in global markets.